IQVIA and NRx Pharmaceuticals Collaborate on Potential Medical Support for Novel COVID-19 Treatment
September 13 2021 - 4:15PM
Business Wire
IQVIA™ (NYSE:IQV), a leading global provider of advanced
analytics, technology solutions and clinical research services to
the life sciences industry, today announced a transformative
collaboration with NRx Pharmaceuticals (NRx) (Nasdaq: NRXP). NRx is
a company dedicated to creating innovative, life-saving treatments
and bringing hope to those facing life-altering conditions with no
approved disease-modifying therapies or cures. IQVIA is excited to
collaborate with NRx as its designated partner, to provide
pharmacovigilance services and medical information in preparation
for potential regulatory actions.
"As the world suffers yet another surge of COVID-19, thousands
of patients require intensive care and too many succumb to this
virus. New medicines with new mechanisms of action are urgently
needed," said Robert Besthof, chief commercial officer and head of
Operations of NRx. "As a small biopharma company preparing to
launch a lifesaving medicine across multiple countries, we deeply
appreciate the global reach that IQVIA is able to offer in support
of patients, families, and those who care for them.”
This collaboration will allow NRx to access IQVIA’s domain
experience with COVID-19, our unparalleled data assets, and
analytics to support potential emergency use authorization (EUA) of
ZYESAMI. IQVIA will work closely with NRx to support key activities
required for EUA activation, including the pharmacovigilance and
medical information programs.
“We are honored by the opportunity to join with NRx on the EUA
activation and compliance for ZYESAMI in treating some of the
sickest patients suffering from COVID-19,” said Susan Kitlas, vice
president, Precommercial Business Unit, IQVIA. “IQVIA’s experience
and expertise within the COVID-19 market will be a valuable
component in helping make this treatment more widely
available.”
About NRx NRx Pharmaceuticals (NASDAQ-GS:NRXP) draws upon
more than 300 combined years of scientific and drug-development
experience to bring improved health to patients. Its
investigational product, ZYESAMI™ (aviptadil) for patients with
COVID-19, has been granted Fast Track designation by the US Food
and Drug Administration and is currently undergoing phase 3 trials
funded by the US National Institutes of Health, the Biomedical
Advanced Research and Development Authority part of the US
Department of Health and Human Services, and the Medical
Countermeasures program, part of the US Department of Defense.
About IQVIA IQVIA (NYSE:IQV) is a leading global provider
of advanced analytics, technology solutions, and clinical research
services to the life sciences industry. IQVIA creates intelligent
connections across all aspects of healthcare through its analytics,
transformative technology, big data resources and extensive domain
expertise. IQVIA Connected Intelligence™ delivers powerful insights
with speed and agility — enabling customers to accelerate the
clinical development and commercialization of innovative medical
treatments that improve healthcare outcomes for patients. With
approximately 74,000 employees, IQVIA conducts operations in more
than 100 countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing information on a scale that helps
healthcare stakeholders identify disease patterns and correlate
with the precise treatment path and therapy needed for better
outcomes. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders tap
into a deeper understanding of diseases, human behaviors and
scientific advances, in an effort to advance their path toward
cures. To learn more, visit www.iqvia.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210913005810/en/
Nick Childs, IQVIA Investor Relations (nick.childs@iqvia.com)
+1.973.316.3828
Tor Constantino, IQVIA Media Relations
(tor.constantino@iqvia.com) +1.484.567.6732
IQVIA (NYSE:IQV)
Historical Stock Chart
From Aug 2024 to Sep 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From Sep 2023 to Sep 2024